Orexo AB (ORXOY)
Market Open
12 Jun, 20:00
OTCQX OTCQX Primary $
1. 80
0
0%
$
71.83M Market Cap
- P/E Ratio
- Div Yield
14 Volume
0 Eps
$ 1.8
Previous Close Want to track ORXOY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
ORXOY trading today higher at $1.8, an increase of 0% from yesterday's close, completing a monthly decrease of -12.1951% or -$0.25. Over the past 12 months, ORXOY stock lost -30.7692%.
ORXOY is not paying dividends to its shareholders.
The last earnings report, released on May 06, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.
Orexo AB (ORXOY) FAQ
What is the stock price today?
The current price is $1.80.
On which exchange is it traded?
Orexo AB is listed on OTCQX.
What is its stock symbol?
The ticker symbol is ORXOY.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 71.83M.
Has Orexo AB ever had a stock split?
No, there has never been a stock split.
Orexo AB Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Nikolaj Sorensen CEO | OTCQX Exchange | 68616W102 CUSIP |
| SE Country | 110 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Orexo AB (publ) stands out as a specialty pharmaceutical company with a devoted focus on developing and commercializing pharmaceuticals and digital therapies. Its operational reach spans the United States, the European Union, and other international markets. Established in 1994 and based in Uppsala, Sweden, Orexo AB has positioned itself as a vital player in offering innovative solutions for the treatment of various disorders, including opioid use disorder, breakthrough pain in cancer patients, and insomnia, among others. Additionally, the company is at the forefront of developing digital therapies aimed at treating depression, managing alcohol consumption, and supporting individuals with opioid use disorder.
Products and Services
- Zubsolv tablets: A medication designed for the treatment of opioid use disorder, providing a therapeutic option for those grappling with this challenging condition.
- Abstral: This product addresses breakthrough pain in cancer patients, offering a significant relief for those in acute discomfort.
- Edluar: Formulated for the treatment of insomnia, Edluar supports individuals in achieving the restorative sleep necessary for health and wellbeing.
- OX124: Currently under development, OX124 is aimed at addressing opioid overdose, showcasing Orexo’s commitment to tackling urgent healthcare challenges.
- OX125: Similar to OX124, OX125 is being developed for use as a rescue medication in cases of opioid overdose, emphasizing the company’s dedication to life-saving treatments.
- OX640: This emergency treatment is being developed for allergic reactions, aiming to provide rapid and effective relief in critical situations.
- OX-MPI: Targeted at the treatment of endometriosis, OX-MPI represents Orexo’s venture into therapeutics for chronic conditions affecting a significant number of individuals.
- deprexis: A digital therapy for the treatment of depression, deprexis leverages technology to deliver mental health support.
- vorvida: This digital therapy is designed for alcohol management, assisting individuals in controlling their alcohol intake.
- modia: Aimed at aiding those with opioid use disorder, modia underlines Orexo’s initiative in combating this widespread issue through digital solutions.
Contact Information
Address: P.O. Box 303
Phone: 46 1 87 80 88 00
Website: https://www.orexo.com
